News
16 January 2024
We are very proud to present our last paper in collaboration with the Institute of Neuroscience of the Universitat de Barcelona, the CiQUS – Center for Research in […]
18 October 2023
Sigma (σ) receptor subtypes, σ1 and σ2, are targets of wide pharmaceutical interest. σ1 receptor ligands are under evaluation in clinical trials for the treatment of diseases such as […]
11 September 2023
A major bottleneck in drug discovery, particularly when targeting transmembrane proteins such as G-coupled receptor proteins (GPCRs), is the challenge of replicating in vitro the precise microenvironment conditions […]
19 July 2023
Traditional pharmacological mechanisms leave a significant part of the genome ‘undruggable’, due to the inability to induce or block their activity using agonists and antagonists. Thanks […]
13 July 2023
Celtarys expands its presence in the GPCR field, developing new applications in collaboration agreement with Nanotemper, a company devoted to the development of innovative instruments for […]
10 July 2023
The fabrication of a particular device depends heavily on the immobilization of the biosensing element (a probe such as an antibody, aptamer, etc.) onto the transducer […]
7 July 2023
Our portfolio of #GPCR#fluorescent ligands is growing.We have just added to our catalogue more fluorescent ligands for the AT1 receptor, CELT-145 and CELT-252. The Angiotensin AT1 receptor belongs to the […]
27 March 2023
Celtarys Research collaborates with several research groups in Europe for the validation of our products in different assays commonly used in drug discovery, always with the […]
7 March 2023
A different way to monitor GPCR binding, target engagement and internalization with a new fluorescent-conjugate toolbox. The past decade has witnessed fluorescently tagged drug molecules gaining […]